FoxA2 involvement in suppression of protein C, an outcome predictor in experimental sepsis

Clinical and Vaccine Immunology

Volumn 13, Issue 3, 2006, Pages 426-432

  Berg, David T ^a   Gerlitz, Bruce ^a   Sharma, Ganesh R ^a   Richardson, Mark A ^a   Stephens, Eddie J ^a   Grubbs, Renee L ^a   Holmes, Kimberly C ^a   Fynboe, Kelly ^a   Montani, Dominick ^a   Cramer, Martin S ^a   Engle, Steven D ^a   Jakubowski, Joseph A ^a   Heuer, Josef G ^a   Grinnell, Brian W ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 3BETA; HEPATOCYTE NUCLEAR FACTOR 6; MESSENGER RNA; PROTEIN C; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SEPSIS;

ACUTE DISEASE; ANIMALS; BASE SEQUENCE; BIOLOGICAL MARKERS; CECUM; DISEASE MODELS, ANIMAL; FEMALE; HEPATOCYTE NUCLEAR FACTOR 3-BETA; LIGATION; MOLECULAR SEQUENCE DATA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN C; PUNCTURES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; RNA, SMALL INTERFERING; SEPSIS;

EID: 33645543709     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.13.3.426-432.2006     Document Type: Article

References (31)

1. Angus, D., W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:1303-1310.
2. Arias, I., W. Jacoby, H. Popper, et al. 1988. The liver: biology and pathobiology, 2nd ed. Raven Press, New York, N.Y.
3. Berg, D. T., L. J. Myers, M. A. Richardson, G. Sandusky, and B. W. Grinnell. 2005. Smad6s regulates plasminogen activator inhibitor-1 through a protein kinase C-beta-dependent up-regulation of transforming growth factor-beta. J. Biol. Chem. 280:14943-14947.
4. Bernard, G., J. Vincent, P. Laterre, S. LaRosa, J. Dhainaut, A. Lopez-Rodriguez, J. Steingrub, G. Garber, J. Helterbrand, E. Ely, and C. Fisher. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344:699-705.
5. Brueckmann, M., U. Hoffmann, L. De Rossi, H. M. Weiler, V. Liebe, S. Lang, J. J. Kaden, M. Borggrefe, K. K. Haase, and G. Huhle. 2004. Activated protein C inhibits the release of macrophage inflammatory protein-1-alpha from THP-1 cells and from human monocytes. Cytokine 26:106-113.
6. Cheng, T., D. Liu, J. Griffin, J. Fernandez, F. Castellino, E. Rosen, K. Fukudome, and B. Zlokovic. 2003. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat. Med. 9:338-342.
7. Duong, D. T., M. E. Waltner-Law, R. Sears, L. Sealy, and D. K. Granner. 2002. Insulin inhibits hepatocellular glucose production by utilizing liver-enriched transcriptional inhibitory protein to disrupt the association of CREB-binding protein and RNA polymerase 11 with the phosphoenolpyruvate carboxykinase gene promoter. J. Biol. Chem. 277:32234-32242.
8. Esmon, C. T., J. M. Gu, J. Xu, D. Qu, D. J. Stearns-Kurosawa, and S. Kurosawa. 1999. Regulation and functions of the protein C anticoagulant pathway. Haematologica 84:363-368.
9. Feistritzer, C., D. H. Sturn, N. C. Kaneider, A. Djanani, and C. J. Wiedermann. 2003. Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. J. Allergy Clin. Immunol. 112:375-381.
10. Fisher, C. J., and S. B. Yan. 2000. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit. Care Med. 28:S49-S56.
11. Grinnell, B., and D. E. Joyce. 2001. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit. Care Med. 29:S53-S61.
12. Heuer, J. G., G. R. Sharma, B. Gerlitz, T. Zhang, D. L. Bailey, C. Ding, D. T. Berg, D. Perkins, E. J. Stephens, K. C. Holmes, R. L. Grubbs, K. A. Fynboe, Y. F. Chen, B. Grinnell, and J. A. Jakubowski. 2004. Evaluation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis. Crit. Care Med. 32:1570-1578.
13. Jacobi, J. 2002. Pathophysiology of sepsis. Am. J. Health Syst. Pharm. 59: S3-S8.
14. Joyce, D. E., L. Gelbert, A. Ciaccia, B. Dehoff, and B. W. Grinnell. 2001. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem. 276:11199-11203.
15. Joyce, D. E., and B. W. Grinnell. 2002. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-κB. Crit. Care Med. 30:S288-293.
16. Joyce, D. E., D. R. Nelson, and B. W. Grinnell. 2004. Leukocyte and endothelial cell interactions in sepsis: relevance of the protein C pathway. Crit. Care Med. 32:S280-S286.
17. Macias, W. L., and D. R. Nelson. 2004. Severe protein C deficiency predicts early death in severe sepsis. Crit. Care Med. 32:S223-S228.
18. Mesters, R., H. Helterbrand, B. G. Utterback, S. B. Yan, B. Chao, and J. A. Fernandez. 2000. Prognostic value of protein C levels in neutropenic patients at high risk of severe septic complications. Crit. Care Med. 28:2209-2216.
19. Mosnier, L. O., and J. H. Griffin. 2003. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease activated receptor-1 and endothelial cell protein C receptor. Biochem. J. 373:65-70.
20. Okajima, K. 2004. Prevention of endothelial cell injury by activated protein C: the molecular mechanism(s) and therapeutic implications. Curr. Vasc. Pharmacol. 2:125-133.
21. Poeze, M., G. Ramsay, H. Gerlach, F. Rubulotta, and M. Levy. 2004. An international sepsis survey: a study of doctors' knowledge and perception about sepsis. Critical Care (London) 8:R409-R413.
22. Rausa, F., Y. Tan, and R. Costa. 2003. Association between hepatocyte nuclear factor 6 (HNF-6) and FoxA2 DNA binding domains stimulates FoxA2 transcriptional activity but inhibits HNF-6 DNA binding. Mol. Cell. Biol. 23:437-449.
23. Riewald, M., R. Petrovan, A. Donner, B. Mueller, and W. Ruf. 2002. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296:1880-1882.
24. Schmide-Supprian, M., C. Murphy, B. White, M. Lawler, A. Kapurniotu, W. Voelter, O. Smith, and J. Bernhagen. 2000. Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes. Eur. Cytokine Netw. 11:407-413.
25. Simpson, K. J., N. C. Henderson, C. L. Bone-Larson, N. W. Lukacs, C. M. Hogaboam, and S. L. Kunkel. 2003. Chemokines in the pathogenesis of liver disease: so many players with poorly defined roles. Clin. Sci. 104:47-63.
26. Spek, C. A., J. S. Greengard, J. H. Griffin, R. M. Bertina, and P. H. Reitsma. 1995. Two mutations in the promoter region of the human protein C gene both cause type 1 protein C deficiency by disruption of two HNF-3 binding sites. J. Biol. Chem. 270:24216-24221.
27. Spek, C. A., V. J. Lannoy, F. P. Lemaigre, G. G. Rousseau, R. M. Bertina, and P. H. Reitsma. 1998. Type 1 protein C deficiency caused by disruption of a hepatocyte nuclear factor (HNF)-6/HNF-1 binding site in the human protein C gene promoter. J. Biol. Chem. 273:10168-10173.
28. Sturn, D. H., N. C. Kaneider, C. Feistritzer, A. Djanani, K. Fukudome, and C. J. Wiedermann. 2003. Expression and function of the endothelial protein C receptor in human neutrophils. Blood 102:1499-1505.
29. Tsay, W., Y. M. Lee, S. C. Lee, M. C. Shen, and P. J. Chen. 1996. Characterization of human protein C gene promoter: insights from natural human mutants. DNA Cell Biol. 15:907-919.
30. Tsay, W., Y. M. Lee, S. C. Lee, M. C. Shen, and P. J. Chen. 1997. Synergistic transactivation of HNF-1α, HNF-3, and NF-I contributes to the activation of the liver-specific protein C gene. DNA Cell Biol. 16:569-577.
31. Uchiba, M., K. Okajima, Y. Oike, Y. Ito, K. Fukudome, H. Isobe, and T. Suda. 2004. Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo. Circ. Res. 95:34-41.